Call for Applications to the CQDM Quantum Leap (Fall 2023)




CQDM’s Quantum Leap pharma-led funding program for drug discovery research helps SMEs or Canadian universities achieve innovative translational biopharmaceutical research projects. Projects selected as part of the Quantum Leap program focus on developing cutting-edge technologies with the potential to significantly advance the R&D activities of CQDM’s pharmaceutical members. Quantum Leap projects are executed in close collaboration and with the expert support and funds of pharmaceutical members.

The enabling technologies, innovative platforms and/or innovative therapies derived from the Quantum Leap pharma-led funding program for drug discovery research are selected for their potential to significantly improve, facilitate and/or accelerate the drug discovery process and the development of safer and more effective drugs. The technologies of interest can be at any stage of the drug development process and involve a wide range of therapeutic indications.

Projects are associated with specific deliverables and must be ready for use by CQDM pharmaceutical members upon completion. For scientists, the funded research opens new collaboration opportunities with world-class stakeholders in the industry. For full application details, visit the CQDM Quantum Leap Program website.


The Quantum Leap pharma-led funding program for drug discovery research is open to all SMEs and public research institutions in Canada.

Because budget structures can vary depending on each project, you must contact CQDM to confirm eligibility before applying (refer to the contact information section)

Funding Availability

CQDM will review applications for its pharma-led funding program for drug discovery research subject to the following:

  • Requested funds must range from $500,000 to $1,200,000. Exceptionally, CQDM may consider applications exceeding the maximum, if appropriate.
  • CQDM pharmaceutical members must have pledged at least one third (1/3) of the funds required to support the project.
  • Applicants are responsible for raising matched funding for the project. When possible, CQDM may offer support to applicants.
  • CQDM may call on a number of national and international partner organizations potentially interested in co-financing certain projects. For example, preliminary discussions with CQDM could help maximize contributions from various partners toward launching a drug discovery research project.
  • Applicants with a secured financial commitment from the industry or from a private, semi-private and public organization (either for-profit or non-profit) could be at an advantage.
  • The funding may consist of a grant or an investment.
  • A detailed breakdown of requested funding must be provided and will be carefully examined by CQDM.
  • Applicants who wish to apply for Mitacs funding (available to graduate students and postdoctoral fellows involved in a CQDM project) must fill out the appropriate Mitacs section on the CQDM application form.

Project Duration

Minimum 1 year, maximum 3 years.


If College-level review is required, your College will communicate its earlier internal deadlines.

Internal Deadline

Applications will be accepted by CQDM until Nov 16, 2023. 

The researcher should submit an OR5 and copy of the EOI to one week prior to the deadline established by CQDM.

External Deadline

The application form can be emailed at any time to

How to Apply

Call for proposals are open year-round for Quantum Leap projects. The deadline to participate in the next selection round is November 16, 2023. Contact Jesse Paterson for more information at

Fill out the Quantum Leap pharma-led funding program for drug discovery research application form. The application form can be emailed at any time to Please feel free to contact Jesse Paterson, Senior Director of Business Development at CQDM if you have any questions.

Please note that CQDM’s pharma-led funding program for drug discovery research involves the close collaboration of applicants and the biopharmaceutical research consortium team. Accordingly, team members may request information before and after the application has been submitted.

Only applicants whose submission has made the shortlist will be invited to submit a revised application, if required, including any additional information required and addressing comments, concerns and questions issued by the interested pharmaceutical members and/or CQDM’s Scientific Advisory Board. 


PDF icon CQDM Overview_Oct 2023.pdf2.7 MB
For Questions, please contact

Jesse Paterson
Senior Director BD

Office of Research

Kaleigh Rajna, Industry Liaison Officer
Research Innovation Office

Alert Classifications
Funding Opportunities and Sponsor News

Health and Life Sciences